SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress.
Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, commented, "Over 2025 and prior years, Antengene has built a solid foundation for long-term growth, including a robust late-stage clinical pipeline, the proprietary AnTenGager$(TM)$ T-cell engager (TCE) platform, and the commercialization of XPOVIO$(R)$ , which is generating revenue across 10 APAC markets. As we enter into 2026, we are beginning to translate this foundation into tangible value creation. Our recent global licensing agreement with UCB for ATG-201 (CD19×CD3 TCE) represents the first out-licensing transaction for the company and the AnTenGager(TM) platform, validating its global competitiveness and marks a clear inflection point for Antengene. Antengene will receive USD 80 million (comprised of an initial upfront payment of USD 60 million and additional near-term milestone payments of USD 20 million), and is eligible to receive more than USD 1.1 billion in success-based development, regulatory and sales milestones, along with tiered royalties on future net sales.
At the same time, our late-stage clinical programs continue to advance. ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) has demonstrated strong efficacy and best-in-class safety in gastric cancer and other CLDN18.2+ solid tumors, with frontline combination studies in gastric cancer underway, positioning upcoming data as a potential key value inflection point. The company plans to initiate a pivotal Phase III monotherapy trial in gastric cancer in 2026, with enrollment starting in the second half of 2026. ATG-037 (oral CD73 small molecule inhibitor) has shown encouraging efficacy in checkpoint inhibitor (CPI) resistant tumors in combination with anti-PD-1 therapy and is well positioned for combination use with next-generation CPIs such as PD-1×VEGF bispecific antibodies. Together, these programs represent important future value drivers as they approach key clinical milestones. In parallel, the AnTenGager(TM) TCE platform will remain open for global collaboration, enabling continued licensing and partnership opportunities. These collaborations represent a new and important revenue stream for the company, with the potential to generate multiple revenue streams through upfront payments, development and regulatory milestones, and potential royalties.
Looking ahead, we will continue to advance our clinical pipeline with disciplined cost control while expanding our innovation capabilities across new and emerging scientific platforms. With multiple novel modalities in development, we believe we are well positioned to further strengthen our R&D engine and support sustainable long-term growth."
Business Updates
1. AnTenGager(TM) TCE Platform
-- TCE platform with steric hindrance masking technology: AnTenGager(TM) is
Antengene's proprietary, second-generation TCE platform featuring "2+1"
bivalent binding for low-expressing targets, steric hindrance masking,
and proprietary CD3 sequences with fast on/off kinetics to minimize
cytokine release syndrome $(CRS)$ and enhance efficacy. These
characteristics support the platform's broad applicability across
autoimmune diseases, solid tumors and hematological malignancies
indications. Leveraging this platform, Antengene has discovered multiple
investigational programs:
-- ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel "2+1"
CD19-targeted T-cell engager developed on the AnTenGager(TM) TCE
platform for the treatment of B cell related autoimmune diseases.
Antengene has entered into a global license agreement with UCB for
ATG-201. The company plans to submit the IND application for
ATG-201 in the first quarter of 2026, and will transfer subsequent
clinical development to UCB upon the completion of the
first-in-human (Phase I) clinical trial. In return of the license
rights granted to UCB, Antengene will receive an upfront and near
term milestone payment of USD 80 million (comprised of an initial
upfront payment of USD 60 million and additional near-term
milestone payments of USD 20 million upon satisfaction of certain
conditions) and would be eligible to receive future success-based
development and commercial milestone payments of over USD 1.1
billion, as well as tiered royalties on future net sales.
-- ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3
targeted TCE being developed for the treatment of ovarian cancer
and kidney cancer. The Company plans to submit an IND application
for ATG-106 in the second quarter of 2027.
-- ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3
targeted TCE being developed for the treatment of gynecological
tumors, digestive system malignancies, bladder cancer and NSCLC.
The Company plans to submit an IND application for ATG-112 in the
second quarter of 2027.
-- Additional TCE programs for solid tumors: Antengene plans to
submit an IND application for ATG-110 (LY6G6D × CD3 TCE) in
the first half of 2027 for the treatment of microsatellite-stable
colorectal cancer. In addition, ATG-115 (an undisclosed bispecific
antibody) and two undisclosed trispecific antibody programs are
currently in preclinical development.
2. Key Clinical Programs
-- ATG-022 (CLDN18.2 Antibody-Drug Conjugate)
-- Data from the Phase II CLINCH study: ATG-022 has demonstrated
potent anti-tumor activity across all levels of CLDN18.2
expression and maintained a favorable safety profile, with the
incidence of Grade 3 or higher treatment-related adverse events
(TRAEs) standing at only 19.4%, suggesting promising potential for
frontline combination therapy. Meanwhile, ATG-022 has also shown
positive efficacy in patients with non-gastrointestinal tumors,
and the Company expects further expansion of its therapeutic
indications to treatable patient populations beyond
gastrointestinal cancers (for detailed data, please refer to the
Company's press release issued in January 2026 at
https://www.antengene.com/newsinfo/459). The Company expects to
release the latest clinical data of ATG-022 in the second quarter
of 2026.
-- Advancing clinical development across 1L to 3L gastric cancer:
Antengene is currently conducting the Phase II CLINCH study and
the Phase Ib/II CLINCH-2 study of ATG-022 in Mainland of China and
Australia. The Company continues to advance the clinical
development of ATG-022 across different lines of gastric cancer
treatment, including first-line therapy in combination with
checkpoint inhibitors (CPIs) and chemotherapy (CAPOX/FOLFOX);
second-line therapy in combination with CPIs; and third-line
therapy as monotherapy, covering patients with varying levels of
CLDN18.2 expression. In addition, the CLINCH study of ATG-022
includes a basket trial cohort evaluating multiple tumor types,
with the majority of patients continuing to receive treatment.
-- ATG-037 (Oral CD73 Small Molecule Inhibitor)
-- Data from the Phase Ib/II STAMINA study: Following the initiation
of a global clinical collaboration with MSD, Antengene is
evaluating ATG-037 in combination with the anti-PD-1 therapy
KEYTRUDA(R) (pembrolizumab) in patients with checkpoint inhibitor
(CPI)-resistant melanoma and non-small cell lung cancer (NSCLC).
These findings suggest that ATG-037 has clinically meaningful
therapeutic potential in multiple tumor types, particularly in
patients who are CPI-resistant (for detailed data, please refer to
the Company's press release issued in November 2025 at
https://www.antengene.com/newsinfo/452). The Company expects to
release the latest clinical data of ATG-037 in the fourth quarter
of 2026.
-- Clinical development pathways: existing data show that ATG-037
holds enormous therapeutic potential for the treatment of
first-line or CPI-resistant melanoma, with promising potential for
expansion into other tumor types. Antengene's clinical development
roadmap for ATG-037 has four main components: 1. combination with
CPI for the treatment of CPI-resistant unresectable and metastatic
melanoma (second-line treatment); 2. combination with CPI for the
first-line treatment of unresectable or metastatic melanoma; 3.
combination with CPI for the treatment of CPI-resistant
unresectable or metastatic NSCLC (second-line treatment); 4.
active expansion into other CPI-resistant tumor types supported by
the encouraging proof-of-concept data; 5. explore potential
combinations with next-generation CPIs such as PD-1×VEGF
bispecific antibody.
-- Combination with PD-1/VEGF Bispecific Antibody: Antengene has
entered into a clinical collaboration agreement with Junshi
Biosciences to evaluate the synergistic therapeutic potential of
Antengene's ATG-037 in combination with Junshi Biosciences' JS207,
(MORE TO FOLLOW) Dow Jones Newswires
March 20, 2026 05:06 ET (09:06 GMT)
